Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

BACKGROUND: The progression of nephropathy from diagnosis of type 2 diabetes has not been well described from a single population. This study sought to describe the development and progression through the stages of microalbuminuria, macroalbuminuria, persistently elevated plasma creatinine or renal...

Bibliográfalaš dieđut
Váldodahkkit:	Adler, A, Stevens, R, Manley, SE, Bilous, R, Cull, C, Holman, R
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2003

Geahča maid

Ethnic differences in diabetic nephropathy - The UKPDS
Dahkki: Stevens, R, et al.
Almmustuhtton: (1999)

Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47).
Dahkki: Adler, A, et al.
Almmustuhtton: (1999)

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.
Dahkki: Turner, R, et al.
Almmustuhtton: (1991)

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
Dahkki: Turner, R, et al.
Almmustuhtton: (1998)

UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.
Dahkki: Kothari, V, et al.
Almmustuhtton: (2002)

Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
Dahkki: Coleman, R, et al.
Almmustuhtton: (2005)

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
Dahkki: Clarke, P, et al.
Almmustuhtton: (2004)

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
Dahkki: Stratton, I, et al.
Almmustuhtton: (2000)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Dahkki: Turner, R, et al.
Almmustuhtton: (1999)

Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29.
Dahkki: Davis, T, et al.
Almmustuhtton: (1999)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
Dahkki: Matthews, DR, et al.
Almmustuhtton: (1998)

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.
Dahkki: Gray, A, et al.
Almmustuhtton: (2000)

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.
Dahkki: Gray, A, et al.
Almmustuhtton: (2000)

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).
Dahkki: Clarke, P, et al.
Almmustuhtton: (2003)

Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.
Dahkki: Davis, T, et al.
Almmustuhtton: (2013)

Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS
Dahkki: Cull, C, et al.
Almmustuhtton: (1999)

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
Dahkki: Cull, C, et al.
Almmustuhtton: (2004)

Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
Dahkki: Cull, C, et al.
Almmustuhtton: (2001)

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group.
Dahkki: Manley, SE, et al.
Almmustuhtton: (2000)

UK PROSPECTIVE DIABETES STUDY (UKPDS) .10. URINARY ALBUMIN EXCRETION OVER 3 YEARS IN DIET-TREATED TYPE-2, (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS, AND ASSOCIATION WITH HYPERTENSION, HYPERGLYCEMIA AND HYPERTRIGLYCERIDEMIA
Dahkki: Cull, C, et al.
Almmustuhtton: (1993)

UKPDS: what was the question? UK Prospective Diabetes Study.
Dahkki: Turner, R, et al.
Almmustuhtton: (1999)

Increased risk of incident heart failure and all-cause mortality in insulin-resistant people with type 2 diabetes in the United Kingdom Prospective Diabetes Study (UKPDS)
Dahkki: Wamil, M, et al.
Almmustuhtton: (2020)

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Dahkki: Gray, A, et al.
Almmustuhtton: (2001)

The natural history of diabetes-related complications: the UKPDS experience. United Kingdom Prospective Diabetes Study.
Dahkki: Matthews, DR
Almmustuhtton: (1999)

The natural history of diabetes-related complications: the UKPDS experience. United Kingdom Prospective Diabetes Study.
Dahkki: Matthews, DR
Almmustuhtton: (1999)

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes
Dahkki: Price, H, et al.
Almmustuhtton: (2007)

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).
Dahkki: Stratton, I, et al.
Almmustuhtton: (2006)

UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.
Dahkki: Stratton, I, et al.
Almmustuhtton: (2001)

Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group.
Dahkki: Horton, V, et al.
Almmustuhtton: (1999)

UNITED-KINGDOM PROSPECTIVE DIABETES STUDY - COMPLIANCE WITH DIET WILL AFFECT RESULTS - REPLY
Dahkki: Holman, R, et al.
Almmustuhtton: (1995)

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Dahkki: Clarke, P, et al.
Almmustuhtton: (2001)

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.
Dahkki: Adler, A, et al.
Almmustuhtton: (2000)

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
Dahkki: Davis, T, et al.
Almmustuhtton: (2001)

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
Dahkki: Kohner, E, et al.
Almmustuhtton: (2001)

Forecasting coronary case fatality in type 2 diabetes: a UKPDS Risk Engine equation
Dahkki: Stevens, R, et al.
Almmustuhtton: (2002)

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
Dahkki: Wright, A, et al.
Almmustuhtton: (2002)

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)
Dahkki: Manley, SE, et al.
Almmustuhtton: (2000)

UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.
Dahkki: Hayes, A, et al.
Almmustuhtton: (2013)

UKPDS Outcomes Model 2: A new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year united kingdom prospective diabetes Study: UKPDS 82
Dahkki: Hayes, A, et al.
Almmustuhtton: (2013)

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).
Dahkki: Stevens, R, et al.
Almmustuhtton: (2001)